3645 results for «2680»
3645 results
Challenges during PCI on bifurcation
20 May 2026 – From EuroPCR 2026
This session addresses the complexities of percutaneous coronary intervention (PCI) in bifurcation lesions. It discusses decision-making strategies, techniques to avoid implanting permanent devices, the use of IVUS-guided laser atherectomy for restenosis, and approaches to challenging double bifurcation lesions including drug-coated balloon therapy.
Optimal use of dedicated device for calcified lesions
20 May 2026 – From EuroPCR 2026
This session delves into the optimal utilization of dedicated devices for managing complex coronary calcification. Explore decision-making strategies involving orbital atherectomy and cutting balloon techniques, as well as advanced approaches like contact intravascular lithotripsy for stented calcified nodules. Additional focus is given to ablative and modifying...
PFO closure - Progression in practice
20 May 2026 – From EuroPCR 2026
This session presents progressive insights into patent foramen ovale (PFO) closure, comparing outcomes across age groups and evaluating residual shunting via transcranial Doppler. It highlights tailored antiplatelet therapy durations from the PROLONG registry, long-term safety and efficacy data, morphological variations of the fossa ovalis, and the...
Stay calm and carry on: bailout techniques for calcified lesions
20 May 2026 – From EuroPCR 2026
Focused on bailout techniques for calcified lesions, this session addresses challenging scenarios such as deformed stents, post-CABG angioplasty complications, and balloon uncrossable lesions in tortuous anatomy. It provides practical approaches to manage complex calcium-related complications that may arise unexpectedly during intervention, ensuring preparedness for difficult procedural...
Drug-coated balloon (DCB) technology: A pioneer’s view of the historical evolution and future directions
08 Jan 2025
In this article, Bruno Scheller explores advances in local drug delivery, from drug-coated balloons to novel antiproliferative agents. These innovations aim to reduce restenosis, minimize permanent implants, and pave the way for patient-specific coronary artery disease treatments.
Author
